Notice of Proposed Sale · 144
Korro Bio, Inc.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Korro Bio, Inc.
- Issuer CIK
- 0001703647
- SEC file number
- 001-39062
- Phone
- 617-468-1999
- Person for whose account securities are to be sold
- Aiyar Ram
- Relationships to issuer
- Officer · Director
- Street
- 60 FIRST STREET
- Street (continued)
- 2ND FLOOR, SUITE 250
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02141
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 5,802 | 662,917.47 | 14,422,571 | 08/04/2026 | NASDAQ | Fidelity Brokerage Services LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- Fidelity Brokerage Services LLC
- Street
- 900 Salem Street
- City
- Smithfield
- State / country code
- RI
- Postal code
- 02917
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/03/2026 | Restricted Stock Vesting | Issuer | 5,802 | N | 08/03/2026 | Compensation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Ram Aiyar | Common | 05/29/2026 | 15,152 | 196,675.99 |
Seller — prior-sale row 1, entry 1
- Name
- Ram Aiyar
- Street
- 60 First Street
- Street (continued)
- 2nd Floor, Suite 250
- City
- Cambridge
- State / country code
- MA
- Postal code
- 02141
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Notice signature
- Notice date
- 08/04/2026
- Signed
- /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ram Aiyar
Company context
Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology. As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutan